360
Participants
Start Date
September 27, 2021
Primary Completion Date
October 16, 2024
Study Completion Date
December 27, 2024
Dupilumab
solution for injection subcutaneous
Omalizumab
solution for injection subcutaneous
Placebo
solution for injection subcutaneous
Investigational Site Number : 3480007, Budapest
Investigational Site Number : 3480004, Budapest
Investigational Site Number : 0560003, Woluwe-Saint-Lambert
Investigational Site Number : 2080001, Copenhagen
Investigational Site Number : 0560002, Leuven
Investigational Site Number : 3480006, Edelény
Investigational Site Number : 3480005, Debrecen
Investigational Site Number : 3480001, Szeged
Investigational Site Number : 3480002, Pécs
Investigational Site Number : 2080003, Aarhus
Investigational Site Number : 0560001, Ghent
Investigational Site Number : 2030010, Prague
Northwell Health Site Number : 8400044, Great Neck
Investigational Site Number : 7240003, Jerez de la Frontera
Investigational Site Number : 2030006, Prague
Investigational Site Number : 2500004, Marseille
Investigational Site Number : 2760002, Berlin
Investigational Site Number : 2030008, Prague
University of Rochester Site Number : 8400015, Rochester
Investigational Site Number : 2030004, Praha 5 - Motole
Investigational Site Number : 3800001, Rozzano
Investigational Site Number : 3800006, Milan
Investigational Site Number : 3800005, Varese
Eastern Virginia Medical School Site Number : 8400010, Norfolk
Investigational Site Number : 7240004, Madrid / Madrid
Investigational Site Number : 7240007, Majadahonda
Investigational Site Number : 2030012, Pilsen
Investigational Site Number : 4840002, Chihuahua City
Investigational Site Number : 2500007, Toulouse
Investigational Site Number : 7240006, Pamplona
Investigational Site Number : 2460002, Tampere
Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400027, Tampa
Investigational Site Number : 4840004, Durango
Investigational Site Number : 2500005, Montpellier
Advanced ENT and Allergy Site Number : 8400013, Louisville
Investigational Site Number : 2760004, Düsseldorf
Investigational Site Number : 7240001, Seville
Optimed Research, LTD Site Number : 8400014, Columbus
Investigational Site Number : 4840003, Guadalajara
Cleveland Clinic Foundation Site Number : 8400029, Cleveland
Investigational Site Number : 2760001, Münster
Investigational Site Number : 2030001, Hradec Králové
Investigational Site Number : 3800004, Florence
Investigational Site Number : 2030002, Pardubice
Investigational Site Number : 2500002, Lille
Northwestern University Site Number : 8400001, Chicago
University of Illinois, Chicago
Investigational Site Number : 6160006, Środa Wielkopolska
University of Missouri Health Care - University Hospital Site Number : 8400016, Columbia
Investigational Site Number : 2030003, Ostrava - Poruba
Allergy, Asthma and Clinical Research Center Site Number : 8400037, Oklahoma City
Essential Medical Research, LLC Site Number : 8400024, Tulsa
University of Texas Health Science Center- Site Number : 8400019, Houston
Investigational Site Number : 2760003, München
Chryaslis Clinical Research Site Number : 8400017, St. George
Investigational Site Number : 2500006, La Roche-sur-Yon
Cedars Sinai Medical Center Site Number : 8400026, Los Angeles
Investigational Site Number : 6160007, Lodz
Investigational Site Number : 2500009, Créteil
Investigational Site Number : 2500008, Le Kremlin-Bicêtre
Investigational Site Number : 3800003, Catania
Oregon Health & Science University Site Number : 8400031, Portland
Investigational Site Number : 6420004, Craiova
Investigational Site Number : 6420002, Brasov
Investigational Site Number : 1240004, London
Investigational Site Number : 1240002, Montreal
Investigational Site Number : 1240003, Québec
Investigational Site Number : 2030007, Benešov
Investigational Site Number : 2460003, Helsinki
Investigational Site Number : 3800002, Rome
Investigational Site Number : 6160004, Poznan
Investigational Site Number : 6160008, Warsaw
Investigational Site Number : 6160005, Katowice
Investigational Site Number : 6160001, Krakow
Investigational Site Number : 6200005, Almada
Investigational Site Number : 6200003, Aveiro
Investigational Site Number : 6200006, Guimarães
Investigational Site Number : 6200001, Matosinhos Municipality
Investigational Site Number : 6200007, Santa Maria da Feira
Investigational Site Number : 7240005, Barcelona
Investigational Site Number : 7240008, L'Hospitalet de Llobregat
Investigational Site Number : 7520003, Gothenburg
Investigational Site Number : 7520002, Lund
Investigational Site Number : 7520001, Stockholm
Investigational Site Number : 8260003, Wigan
Investigational Site Number : 8260002, Manchester
Investigational Site Number : 8260001, Newcastle upon Tyne
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY